Evidence map›Paper›PMID 34316045›Full record

ReviewNature reviews. Endocrinology2021

Improving clinical outcomes through attention to sex and hormones in research.

Michelle M Mielke, Virginia M Miller

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Redesigning medicine: integrating sex and gender for better health outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Four dimensions of individualization in brain stimulation for psychiatric disorders: context, target, dose, and timing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Michelle M MielkeDivision of Epidemiology, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA. Mielke.Michelle@mayo.edu.ORCID http://orcid.org/0000-0001-7177-1185
Virginia M MillerMayo Clinic Specialized Center of Research Excellence, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseU54AG044170 · NIA · MAYO CLINIC ROCHESTER · PI KAPOOR, EKTA · 2018 to 2022
$7.7M
Sex-specific Risk for Vascular Dysfunction and Cognitive DeclineP50AG044170 · NIA · MAYO CLINIC ROCHESTER · PI MILLER, VIRGINIA M · 2012 to 2017
$6.1M
Reproductive risk factors for Alzheimer's disease dementia and pathologyRF1AG055151 · NIA · MAYO CLINIC ROCHESTER · PI MIELKE, MICHELLE M, ROCCA, WALTER A · 2017 to 2017
$4.0M
NIA NIH HHS P50 AG044170NIA NIH HHS RF1 AG055151NIA NIH HHS U54 AG044170
6 · The paper itself

Abstract

Biological sex, fluctuations in sex steroid hormones throughout life and gender as a social construct all influence every aspect of health and disease. Yet, for decades, most basic and clinical studies have included only male individuals. As modern health care moves towards personalized medicine, it is clear that considering sex and hormonal status in basic and clinical studies will bring precision to the development of novel therapeutics and treatment paradigms. To this end, funding, regulatory and policy agencies now require inclusion of female animals and women in basic and clinical studies. However, inclusion of female animals and women often does not mean that information regarding potential hormonal interactions with pharmacological treatments or clinical outcomes is available. All sex steroid hormones can interact with receptors for drug targets, metabolism and transport. Genetic variation in receptors or in enzymatic function might contribute to sex differences in therapeutic efficacy and adverse drug reactions. Outcomes from clinical trials are often not reported by sex, and, if the data are available, they are not translated into clinical practice guidelines. This Review will provide a historical perspective for the current state of research related to hormone trials and provide concrete strategies that, if implemented, will improve the health of all people.

Indexed as

Drug-Related Side Effects and Adverse ReactionsGonadal Steroid HormonesSex CharacteristicsTreatment OutcomeAnimalsFemaleHumansMalePrecision MedicineGonadal Steroid Hormones

Identifiers

PMID34316045
PMCPMC8435014
OpenAlexW3186034789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.